Trial · NCT03119714
Pemirolast in Allergen Challenge (PEMAG)
NCT03119714, Phase 2, Terminated, Karolinska University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pemirolast in Allergen Challenge (PEMAG). Trials, record NCT03119714. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03119714
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pemirolast in Allergen Challenge (PEMAG)
- NCT number
- NCT03119714
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Karolinska University Hospital
- Conditions
- Allergic Asthma
- Interventions
- Pemirolast, Placebo Oral Tablet
- First posted
- 2017-04-19
- Last updated
- 2019-05-08
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Bronchoconstriction measured as fall in FEV1 during the early (EAR) and late (LAR) asthmatic reaction induced by allergen | After treatment with pemirolast or matching placebo for 14-16 days | |
| Secondary | Mast cell activation measured as urinary excretion of metabolites of lipid mediators (prostaglandins,isoprostanes,leukotrienes,tromboxanes) | After treatment with pemirolast or matching placebo for 14-16 days | Urine samples will be analysed with mass spectrometry (UPLC-MS/MS) and data presented as ng.mmol creatinine-1 for all metabolites |
| Secondary | Airway inflammation measured as the percentage of sputum eosinophils | After treatment with pemirolast or matching placebo for 14-16 days | Induced sputum will be collected 7 hours after the last inhaled allergen dose and percentage of eosinophils will be measured |
| Other | Airway responsiveness expressed as methacholine PD20FEV1 | After treatment with pemirolast or matching placebo for 14-16 days | Change in methacholine responsiveness after the allergen challenge will be compared during the two treatment periods |
| Other | Measurement of inflammatory biomarkers in saliva | After treatment with pemirolast or matching placebo for 14-16 days | Saliva is collected before and after challenges to monitor activation of mast cells and other inflammatory pathways |
| Other | Measurement of biomarkers in blood | After treatment with pemirolast or matching placebo for 14-16 days | Venous blood samples are collected at clinic visits for asthma biomarkers. Biomarkers are taken before and after challenges according to sub-protocols specific for each analyte. |
| Other | Measurement of biomarkers in sputum | After treatment with pemirolast or matching placebo for 14-16 days | Sputum induction is performed on particular study days to assess inflammatory cell content and to collect sputum supernatant for analysis of biomarkers. |
| Other | Measurement of biomarkers in exhaled breath samples | After treatment with pemirolast or matching placebo for 14-16 days | Collection of exhaled air using the eNose will be used for exploratory studies of specific volatile and particular components of the exhaled breath |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03119714
GET https://conductscience.org/api/trials/v1/NCT03119714/registered